"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 5 | 3 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 4 | 1 | 5 |
| 2011 | 3 | 1 | 4 |
| 2012 | 5 | 7 | 12 |
| 2013 | 5 | 3 | 8 |
| 2014 | 5 | 3 | 8 |
| 2015 | 9 | 6 | 15 |
| 2016 | 7 | 7 | 14 |
| 2017 | 9 | 7 | 16 |
| 2018 | 15 | 6 | 21 |
| 2019 | 6 | 6 | 12 |
| 2020 | 7 | 9 | 16 |
| 2021 | 7 | 6 | 13 |
| 2022 | 0 | 11 | 11 |
| 2023 | 0 | 4 | 4 |
| 2024 | 4 | 10 | 14 |
| 2025 | 10 | 7 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis. Am J Kidney Dis. 2026 Mar; 87(3):313-323.
-
Selpercatinib Increases Radioactive Iodine Avidity in RET-Fusion Pediatric Thyroid Carcinoma. Pediatrics. 2025 Dec 01; 156(6).
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. JAMA. 2025 11 25; 334(20):1816-1826.
-
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan; 37(1):53-68.
-
COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale. Nat Commun. 2025 Sep 30; 16(1):8373.
-
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025 Aug 12; 9(15):3728-3738.
-
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma. CPT Pharmacometrics Syst Pharmacol. 2025 Oct; 14(10):1562-1574.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Late Recurrence of Spindle Cell Sarcoma in Association with TPM3::NTRK1 Fusion. Int J Surg Pathol. 2025 Dec; 33(8):1709-1712.